PIP4K2

PIP4K2

The PIP4K2 project is licensed to Petra Pharma and is run in a collaboration in which Petra Pharma is responsible for all development costs.

The target protein in this project, PIP4K2, is a lipid kinase with an important role in, among other things, different forms of leukemia. Behind the discovery of this target protein and its role in cancer is one of Petra Pharma’s founder, Dr Lewis Cantley. Four of Petra Pharma’s founders are large pharmaceutical companies (AbbVie, Pfizer, Johnson and Johnson Innovation and Eli Lilly), providing Petra Pharma with both the scientific skills and the financial muscles required to drive this project in the best manner to the clinic.